US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

GRAIL, Inc. - Common Stock (NQ:GRAL)

143.43 -15.49 (-9.75%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GRAIL, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
GRAL ALERT: Kaplan Fox is Investigating Grail, Inc. (NASDAQ: GRAL) for Potential Securities Law Violations
NEW YORK, NY - February 23, 2026 (NEWMEDIAWIRE) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Grail, Inc. (“Grail” or the “Company”) (Nasdaq: GRAL). 
Via TheNewswire.com
News headline image
GRAL ALERT: Kaplan Fox is Investigating Grail, Inc. (NASDAQ: GRAL) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
News headline image
Here's Why Grail Stock Slumped Again Today ↗
The company continues to come under pressure after a very disappointing trial result. 
Via The Motley Fool
News headline image
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% ↗
GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions. 
Via The Motley Fool
Topics Regulatory Compliance
GRAIL INC (NASDAQ:GRAL) Plummets 47% Despite Narrower-Than-Expected Q4 Loss ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Here's Why Grail Stock Crashed 50% Today ↗
The top-line results from its landmark trial were not good, but there's more data to come, and it might prove more favorable for investors. 
Via The Motley Fool
Top movers in Friday's session ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Which stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone ↗
Baird analyst Catherine Ramsey Schulte slashed the price target on Grail to $82 from $113 while reiterating an ‘Outperform’ rating. 
Via Stocktwits
News headline image
Why Grail Stock Is Sinking Friday ↗
GRAIL (NASDAQ: GRAL) shares plunged after the NHS-Galleri trial failed to meet its primary endpoint. Explore the trial results. 
Via Benzinga
News headline image
Nasdaq, S&P 500 Futures Rise Before PCE Report, Likely Tariff Ruling: Why NVDA, TSLA, GOOGL, IBRX, APP, GRAL Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on QQQ turned bearish amid elevated message volume. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
From Johnson Fistel, PLLP
Via Business Wire
News headline image
GRAL Stock Slumps After Hours As Trial For Cancer Test Fails To Show Reduction In Late-Stage Diagnoses ↗
The trial did not show a statistically significant reduction in Stage III-IV cancer diagnoses, the company said. 
Via Stocktwits
Topics Artificial Intelligence Death
Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
Via Chartmill
News headline image
Here's Why This Exciting Healthcare Stock Popped 13% Today ↗
Investors are getting excited by the prospects for Grail's Galleri test in 2026. 
Via The Motley Fool
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an... 
Via MarketMinute
News headline image
Small-Cap Standouts: These 3 Stocks Rose Over 300% in 2025 ↗
Via MarketBeat
News headline image
Here's Why Grail Soared, Again, in November ↗
A combination of operational improvements and developments at its key rival bolstered the stock recently. 
Via The Motley Fool
News headline image
Why GRAIL Stock Could Be Biotech’s Next Big Breakout ↗
Via MarketBeat
News headline image
Why Grail Stock Zoomed Nearly 7% Higher on Monday ↗
The company has significant potential with its comprehensive cancer test. 
Via The Motley Fool
News headline image
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
GRAIL (GRAL) Q3 2025 Earnings Call Transcript ↗
GRAIL (GRAL) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
GRAIL INC (NASDAQ:GRAL) Q3 2025 Earnings: Tops Revenue and EPS Estimates as Galleri Sales Climb ↗
GRAIL (GRAL) Q3 2025 earnings beat estimates on revenue and EPS, sending the stock higher. Strong growth for its Galleri cancer test drove the positive results. 
Via Chartmill
Topics Earnings
News headline image
Here's Why Grail Stock Exploded Higher by 55% in October ↗
The company demonstrated tangible progress on its path to profitability. 
Via The Motley Fool
News headline image
Grail Stock Is Up 80% Over the Past Month. Here's Why. ↗
This cancer detection test maker just got some great news. 
Via The Motley Fool
News headline image
Grail's CEO Sells 7,200 Shares for nearly $500,000 ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
WW International, Replimune Group, Datavault AI, GRAIL And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 Next >